Answers are grounded in this paper and cite their sources.
PTR-1 is an investigator-initiated, open-label, randomized phase II trial evaluating whether primary tumor resection (PTR) after disease control with afatinib improves progression-free survival (PFS) in patients with stage IV EGFR-mutant non-small-cell lung cancer. Planned enrollment is 100 participants, with an initial target of 60 randomized participants. Eligible patients are aged ≥20 years, have an EGFR exon 19 deletion or exon 21 L858R mutation, an Eastern Cooperative Oncology Group performance status of 0–1, and a technically resectable primary tumor. Participants receive 12 weeks of afatinib induction, including treatment before enrollment. Those with a partial response or stable disease who remain medically fit and surgically eligible are randomized 1:1 to PTR plus continued afatinib or afatinib alone. The primary endpoint is the 2-year PFS rate from the first afatinib dose. PFS is defined as the time from afatinib initiation to progression per RECIST version 1.1 or death from any cause. Secondary endpoints include PFS, overall survival, safety, pathological response, and resection margin status. PTR-1 evaluates whether resection of the residual primary tumor improves disease control in patients eligible for randomization after induction. Clinical trial registration www.clinicaltrials.gov identifier is NCT05215548.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: